“It was at Halozyme where Dr. Frost acquired his penchant for applying speed to large molecule therapy. Now, as Chairman and CEO at EXUMA Biotech, he’s applying that penchant to the administration of cell and gene therapies. That’s a considerably more complicated—and daunting—mission. Reducing the administration time of monoclonal antibodies, for instance, from 8 hours (intravenous) to under five minutes (subcutaneous) is a challenge. Reducing the time it takes to process and administer CAR-T cells from 20-40 days to less time than a typical workday? That’s a very ambitious challenge.”
